COVID update: new waves of BA.4 and BA.5 in the UK – all omicron variants linked to reduced antibody responses to vaccines
1 July 2022. Related: Coinfections and complications, COVID-19: vaccine research, COVID-19.
COVID-19: vaccine research
Importance of booster vaccine to protect against emergent COVID-19 variants
1 July 2022. Related: Coinfections and complications, COVID-19: vaccine research, COVID-19.
Similar COVID-19 vaccination responses in HIV positive people on ART and with good CD4 counts compared to HIV negative controls
1 July 2022. Related: Coinfections and complications, COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
US study reports higher rates of breakthrough COVID in HIV positive vs negative controls
1 July 2022. Related: Coinfections and complications, COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Two new platform vaccines against COVID-19 report phase 3 results
2 May 2022. Related: Coinfections and complications, Other news, COVID-19: vaccine research, COVID-19.
Temporary protection against omicron needs mRNA booster: limited data for those at highest risk
1 April 2022. Related: COVID-19: vaccine research, COVID-19.
Efficacy of mRNA vaccines in people with HIV or solid transplant recipients
8 March 2022. Related: COVID-19: vaccine research, COVID-19.
Myocarditis and pericarditis after COVID-19 vaccines
20 December 2021. Related: COVID-19: vaccine research, COVID-19.
Durability of immune responses to COVID-19 vaccines in HIV positive people
31 October 2021. Related: COVID-19: vaccine research, COVID-19.
Sputnik V vaccine not approved in South Africa due to potential increased risk of HIV
31 October 2021. Related: COVID-19: vaccine research, COVID-19.
Sanofi reports phase 1/2 mRNA results but withdraws from further COVID19 vaccines
31 October 2021. Related: COVID-19: vaccine research, COVID-19.
BHIVA statements on third vaccine doses for people living with HIV
17 September 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
UK vaccine programme saved 100,000 lives
17 September 2021. Related: COVID-19: vaccine research, COVID-19.
Large US registry confirms safety of COVID-19 vaccines during pregnancy
17 September 2021. Related: COVID-19: vaccine research, COVID-19.
US FDA grants full approval to Pfizer vaccine
17 September 2021. Related: COVID-19: vaccine research, COVID-19.
Immune responses against Delta variant in people vaccinated in the UK
17 September 2021. Related: COVID-19: vaccine research, COVID-19.
Neutralising antibody levels from COVID vaccines correlate negatively with age
17 September 2021. Related: COVID-19: vaccine research, COVID-19.
Evolution of neutralising antibody responses to natural infection and after vaccination
17 September 2021. Related: COVID-19: vaccine research, COVID-19.
Antibody responses to Pfizer vaccine in HIV positive people with high CD4 counts
1 August 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Third dose of mRNA vaccine improves antibody responses in kidney transplant recipients
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
US CDC recommends third vaccine dose in some groups
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
Pfizer plans for third dose: questions over population need?
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
Efficacy of Oxford/AZ and Pfizer vaccines against Delta variant in the UK
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
Results from Novavax phase 3 study in the UK
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
WHO approves Chinese vaccines for emergency use
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
Selected other vaccine studies
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
Efficacy of Chinese CoronaVac vaccine in Chile national programme
1 August 2021. Related: COVID-19: vaccine research, COVID-19.
London HIV study of responses to COVID-19 vaccines and natural infection (SCAPE)
1 July 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19: research studies, COVID-19.
mRNA vaccine fails to produce antibody response in late-stage HIV: low CD4 count and high viral load
1 July 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Special report on background incidence of adverse events in vaccine studies
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
Third vaccine dose increases immune response to 68% in French transplant recipients
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
Third COVID-19 vaccine dose in US cohort of people on immune-suppressing treatment: safety and ethical issues
1 July 2021. Related: COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
Plans for universal third vaccine dose for UK adults from September
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
COVID-19 vaccines increase sperm quality: potential to help uptake
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
MHRA authorises Janssen/J&J COVID-19 vaccination in the UK
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Reduced antibody responses to first dose of mRNA COVID-19 vaccines in HIV positive people with a lower CD4 count
1 June 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
France routinely recommends third dose of COVID-19 vaccine for some people with reduced immune function
1 June 2021. Related: COVID-19: vaccine research, COVID-19: guidelines, COVID-19.
US CDC reports 10,000 breakthrough infections after full vaccination: showing success of vaccine programme
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Cases of COVID-19 reported including deaths in care home residents after full-course vaccination
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Israeli study reports reduced vaccine efficacy in people with immune suppression until 14 days after the second dose
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Novavax reports 43% efficacy against B.1.351 South African variant but negative impact in HIV positive participants
1 June 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Oxford/AZ vaccine linked to 242 rare bloods clots in the UK: alternative recommended for people younger than 40
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
COVID-19 vaccine candidate from GSK and Sanofi to move to phase 3 placebo controlled study
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Similar immune responses to the Oxford/AZ COVID vaccine reported In HIV positive people with high CD4 counts
3 May 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Low responses to mRNA COVID-19 vaccines in those older than 80 vs <60 years and in recipients of solid organ transplants
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
Two cases of viral breakthrough infections despite full protection from Pfizer mRNA vaccination
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
US post-authorisation safety data on Pfizer and Moderna vaccines
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
EMA review of Oxford/AZ vaccine and rare blood clots reported in the EU
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
Interim results report 80% efficacy for India’s COVAXIN vaccine
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
Three new COVID-19 vaccine studies enrolling in the UK
3 May 2021. Related: COVID-19: vaccine research, COVID-19: research studies, COVID-19.
US phase 3 results enable FDA review of the Oxford/AstraZeneca vaccine
1 April 2021. Related: COVID-19: vaccine research, COVID-19.
Janssen/J&J vaccine against COVID-19 is approved in the EU
12 March 2021. Related: COVID-19: vaccine research, COVID-19.
HIV positive people in the UK now elligible for COVID vaccinations – and to become available at HIV clinics
24 February 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
What are the main COVID-19 variants? How can they affect vaccine responses?
24 February 2021. Related: COVID-19: vaccine research, COVID-19: transmission & prevention, COVID-19.
Novavax: >90% efficacy in UK but 60% in South Africa, hints of lower effect in HIV positive participants
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Russian Sputnik vaccine reports 91% efficacy at 21 days after the first dose
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Janssen vaccine reports efficacy after single injection: FDA decision imminent
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Oxford/AZ vaccine might still prevent severe COVID-19 from B.1.351 variant: supports continued used in South Africa
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Unprecedented rapid speed of COVID vaccine development
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
WHO online vaccine tracker
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
COVID-19 vaccine pricing: a BBC guide
24 February 2021. Related: COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
Pfizer COVID-19 vaccine might still overcome UK and SA variants
22 January 2021. Related: COVID-19: vaccine research, COVID-19.
Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico
22 January 2021. Related: COVID-19: vaccine research, COVID-19.
Merck/MSD withdraws two vaccine candidates from further research but continues focus on treatment
22 January 2021. Related: COVID-19: vaccine research, COVID-19: investigational drugs, COVID-19.
Early safety and immune responses in older people using the Oxford vaccine: overall results complicated by dosing error
9 December 2020. Related: COVID-19: vaccine research, COVID-19.